Find Psychiatry/Psychology Drugs in Phase III Clinical Development in CANADA

Lead Product(s): Risperidone

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia.